Literature DB >> 19421773

Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications.

Manohar Pradhan1, Ben Davidson, Claes Göran Tropé, Håvard Emil Danielsen, Vera Maria Abeler, Björn Risberg.   

Abstract

Our objective was to study the gross genomic alterations in serous borderline tumors and serous adenocarcinomas of the ovary. A retrospective analysis of 245 serous borderline tumors and 62 serous adenocarcinomas from 249 patients was performed using high-resolution image cytometric DNA ploidy analysis. DNA ploidy status, S-phase fraction, and DNA index were evaluated. The majority of serous borderline tumors were diploid (225/245 cases, 92%). The remaining 8% showed an aneuploid peak predominantly with DNA index of less than 1.4. Grades 2 and 3 serous adenocarcinomas were more often (80%) nondiploid, mostly with DNA index exceeding 1.4. Grade 1 serous adenocarcinomas were an intermediate group, more similar to serous borderline tumors. The S-phase fraction increased from serous borderline tumors (mean = 0.6%) through grade 1 serous adenocarcinomas (mean = 2.8%), being highest in grades 2 and 3 adenocarcinomas (mean = 6.8%). Our findings support the hypothesis that serous borderline tumors and grades 2 and 3 serous adenocarcinomas are genomically different lesions, with grade 1 serous adenocarcinomas being an intermediate group more close to borderline tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19421773     DOI: 10.1007/s00428-009-0778-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  28 in total

1.  Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.

Authors:  Lovisa Osterberg; Margaretha Akeson; Kristina Levan; Karolina Partheen; Britt-Marie Zetterqvist; Mats Brännström; György Horvath
Journal:  Cancer Genet Cytogenet       Date:  2006-06

2.  Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization.

Authors:  N G Wolf; F W Abdul-Karim; C Farver; E Schröck; S du Manoir; S Schwartz
Journal:  Genes Chromosomes Cancer       Date:  1999-08       Impact factor: 5.006

3.  DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary.

Authors:  J. Kaern; C.G. Tropé; G.B. Kristensen; V.M. Abeler; E.O. Pettersen
Journal:  Int J Gynecol Cancer       Date:  1993-11       Impact factor: 3.437

4.  The role of DNA flow cytometry in borderline malignant ovarian tumors.

Authors:  C H Lai; S Hsueh; T C Chang; C J Tseng; K G Huang; H H Chou; S M Chen
Journal:  Cancer       Date:  1996-08-15       Impact factor: 6.860

5.  Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases.

Authors:  M de Nictolis; R Montironi; S Tommasoni; S Carinelli; B Ojeda; X Matías-Guiu; J Prat
Journal:  Cancer       Date:  1992-07-01       Impact factor: 6.860

6.  Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.

Authors:  M K Dodson; L C Hartmann; W A Cliby; K A DeLacey; G L Keeney; S R Ritland; J Q Su; K C Podratz; R B Jenkins
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

7.  The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study.

Authors:  Marjolijn B Verbruggen; Paul J van Diest; Jan P Baak; Mark A M Broeckaert; Peter Kenemans; René H M Verheijen
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

8.  Prognostic significance of nuclear DNA content in serous ovarian tumors.

Authors:  K Erhardt; G Auer; E Björkholm; G Forsslund; B Moberger; C Sifverswärd; G Wicksell; A Zetterberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

Review 9.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

10.  DNA flow cytometric analysis of serous ovarian tumors of low malignant potential.

Authors:  J D Seidman; H J Norris; J L Griffin; C L Hitchcock
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

View more
  7 in total

1.  Whole exome sequence analysis of serous borderline tumors of the ovary.

Authors:  Jeff Boyd; Biao Luo; Suraj Peri; Beth Wirchansky; Lucinda Hughes; Caitlin Forsythe; Hong Wu
Journal:  Gynecol Oncol       Date:  2013-06-14       Impact factor: 5.482

Review 2.  Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

Authors:  Håvard E Danielsen; Manohar Pradhan; Marco Novelli
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

3.  Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.

Authors:  Manohar Pradhan; Björn A Risberg; Claes G Tropé; Matt van de Rijn; C Blake Gilks; Cheng-Han Lee
Journal:  BMC Cancer       Date:  2010-09-15       Impact factor: 4.430

Review 4.  Recent concepts of ovarian carcinogenesis: type I and type II.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Ikuo Konishi
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

5.  DNA Cytometry and Nuclear Morphometry in Ovarian Benign, Borderline and Malignant Tumors.

Authors:  Amina A Gamal El Din; Manal A Badawi; Shereen E Abdel Aal; Nihad A Ibrahim; Fatma A Morsy; Nermeen M Shaffie
Journal:  Open Access Maced J Med Sci       Date:  2015-10-01

Review 6.  Subtypes of Ovarian Cancer and Ovarian Cancer Screening.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Ikuo Konishi
Journal:  Diagnostics (Basel)       Date:  2017-03-02

7.  Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.

Authors:  C Blake Gilks
Journal:  J Oncol       Date:  2009-12-30       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.